Roche has long held a leadership position in oncology – even if it has not held onto that lead in immuno-oncology – but with its investments in digital and personalized health care, it is looking establish its position as an oncology leader in the future.
The company used its annual on-site investor briefing at the American Society of Clinical Oncology annual meeting to review the data across its oncology portfolio and explain how its combination...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?